KALADRUG-R
New tools for monitoring drug resistance and treatment response in visceral leishmaniasis in the Indian subcontinent
| Coordinatore | PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE
Organization address
address: Nationalestraat 155 contact info |
| Nazionalità Coordinatore | Belgium [BE] |
| Totale costo | 3˙972˙950 € |
| EC contributo | 2˙999˙998 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-SICA |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-11-01 - 2013-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE
Organization address
address: Nationalestraat 155 contact info |
BE (ANTWERPEN) | coordinator | 0.00 |
| 2 |
BANARAS HINDU UNIVERSITY
Organization address
address: BHU contact info |
IN (VARANASI) | participant | 0.00 |
| 3 |
BP KOIRALA INSTITUTE OF HEALTH SCIENCES
Organization address
address: Ghopa contact info |
NP (DHARAN) | participant | 0.00 |
| 4 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 0.00 |
| 5 |
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
Organization address
address: Anusandhan Bhawan, Rafi Marg 2 contact info |
IN (NEW DEHLI) | participant | 0.00 |
| 6 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 0.00 |
| 7 |
GENOME RESEARCH LIMITED
Organization address
address: THE GIBBS BUILDING, EUSTON ROAD 215 contact info |
UK (LONDON) | participant | 0.00 |
| 8 |
Indian Council of Medical Research
Organization address
address: Ansari Nagar contact info |
IN (New Delhi) | participant | 0.00 |
| 9 |
UNIVERSITEIT ANTWERPEN
Organization address
address: PRINSSTRAAT 13 contact info |
BE (ANTWERPEN) | participant | 0.00 |
| 10 |
UNIVERSITY OF STRATHCLYDE
Organization address
address: Richmond Street 16 contact info |
UK (GLASGOW) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Visceral leishmaniasis (VL), one of the most-neglected infectious diseases, has an annual incidence of 500,000 cases. Early treatment is a major pillar of the current program for VL elimination on the Indian sub-continent. However, the arsenal of available drugs is very limited, and their use is jeopardized by drug resistance. Combination regimens for VL are under clinical development, but it will take several more years to change the drug policy. Meanwhile, the effectiveness of current drugs needs to be safeguarded in order to cure patients and ensure unremitting sustainment of VL control. For this, the uninterrupted supply of quality drugs, the promotion of treatment compliance and, the monitoring of treatment effectiveness and of drug resistance will be pivotal. The latter demands improved knowledge and know-how, hence clinical and laboratory research are urgently needed to support the drug policy of the VL elimination program. The present multi-disciplinary proposal addresses these needs: we aim to develop, evaluate and disseminate new tools for the assessment of drug resistance in L. donovani as well as innovative methodologies for monitoring Kala-Azar treatment effectiveness under routine conditions.'
Introduzione (Teaser)
Visceral leishmaniasis is one of the most neglected infectious diseases. Timely and effective treatment is crucial to current elimination efforts on the Indian subcontinent.
Descrizione progetto (Article)
Visceral leishmaniasis (VL), sometimes known as kala-azar or black fever, is a severe form of leishmaniasis - a disease caused by protozoan parasites of the Leishmania variety. According to reports, it is the second-largest parasitic killer in the world (after malaria), responsible for some 500;000 cases each year worldwide. Several species of Leishmania are known to prompt the visceral form of the disease, including L. donovani and L. infantum.
Combating visceral leishmaniasis (VL) calls for improved drug availability, supply, administration, effectiveness and control. Even when given to sufferers, resistance to the drug causes further concern. For this reason, the effectiveness of drugs distributed has to be monitored and protected so that patients can be cured and VL brought under control.
Although clinical development of combination regimens for VL is progressing, it will be years before drug policy will bring about changes. 'New tools for monitoring drug resistance and treatment response in visceral leishmaniasis in the Indian sub-continent' (Kaladrug-R) aims to develop, evaluate and provide tools that can assess drug resistance in L. donovani. Successes in this effort will provide for a steady supply of quality drugs and promotion of appropriate treatment.
Monitoring the effectiveness of treatment and possible resistance to drugs fighting kala-azar calls for improved eradication programmes and know-how. Kaladrug-R is helping to organise clinical and laboratory research which are needed to support the drug policy underpinning any resulting VL elimination campaign.